18F-mFBG for intravenous administration

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cardiovascular Diseases

Conditions

Cardiovascular Diseases

Trial Timeline

Nov 5, 2021 → Mar 7, 2025

NCT ID

NCT04535193

About 18F-mFBG for intravenous administration

18F-mFBG for intravenous administration is a phase 1/2 stage product being developed by Illumina for Cardiovascular Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT04535193. Target conditions include Cardiovascular Diseases.

What happened to similar drugs?

9 of 20 similar drugs in Cardiovascular Diseases were approved

Approved (9) Terminated (2) Active (9)

🔄polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3

🔄Dulaglutide + PlaceboEli LillyPhase 3

🔄raloxifene + placeboEli LillyPhase 3

🔄Orforglipron + PlaceboEli LillyPhase 3

✅Rosuvamibe + MonorovaYuhanApproved

✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved

✅Rosuvamibe + MonorovaYuhanApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04535193	Phase 1/2	Completed	Nov 5, 2021	Mar 7, 2025	Cardiovascular Diseases

Competing Products

20 competing products in Cardiovascular Diseases

See all competitors

Product	Company	Stage	Hype Score
polypill + Usual cardiovascular medications	Dr. Reddy's Laboratories	Phase 3	37
Dulaglutide + Placebo	Eli Lilly	Phase 3	40
raloxifene + placebo	Eli Lilly	Phase 3	40
Evacetrapib	Eli Lilly	Phase 1	29
Orforglipron + Placebo	Eli Lilly	Phase 3	47
Prasugrel (CS-747) + Clopidogrel	Eli Lilly	Phase 2	35
Rosuvamibe + Monorova	Yuhan	Approved	39
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin	Yuhan	Approved	43
Rosuvamibe + Monorova	Yuhan	Approved	43
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)	Daiichi Sankyo	Approved	43
Lexiscan	Astellas Pharma	Phase 2	35
mirabegron + tamsulosin	Astellas Pharma	Phase 1	29
TRC150094	Torrent Pharmaceuticals	Phase 1/2	32
Lorcaserin hydrochloride + Placebo	Eisai	Approved	43
Lepodisiran Sodium + Placebo	Eli Lilly	Phase 3	44
Retatrutide + Placebo	Eli Lilly	Phase 3	44
Empagliflozin + Placebos	Eli Lilly	Approved	43
Evacetrapib + Placebo	Eli Lilly	Phase 3	32
Placebo + AZD0780	AstraZeneca	Phase 2	35
Risk of low dose aspirin discontinuation	AstraZeneca	Pre-clinical	26